论文部分内容阅读
目的观察培哚普利联合厄贝沙坦治疗扩张型心肌病(DCM)大鼠的疗效。方法腹腔注射阿霉素建立SD大鼠DCM模型。13周后,大鼠分为4组A组为正常大鼠,B组为DCM大鼠,均不予药物干预;C组、D组均为DCM大鼠,C组予以培哚普利,D组予以培哚普利联合厄贝沙坦。比较各组干预3周前后血脑利钠肽(BNP)水平,左室射血分数(LVEF)及干预后心肌病理改变。结果①D组BNP水平低于C组(P<0.05);②D组LVEF高于C组(P<0.05);③C、D组心肌病理损害得以减轻(P<0.01)。结论培哚普利联合厄贝沙坦治疗DCM大鼠,在改善心功能方面优于单用培哚普利;两种方案均可减轻心肌病理损害。
Objective To observe the curative effect of perindopril and irbesartan on dilated cardiomyopathy (DCM) rats. Methods Intraperitoneal injection of doxorubicin was used to establish SD rat model of DCM. After 13 weeks, the rats were divided into 4 groups A normal rats, B group DCM rats, no drug intervention; C group, D group were DCM rats, C group were perindopril, D Patients were given perindopril combined with irbesartan. The levels of blood brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) and myocardial pathological changes were compared before and after intervention for 3 weeks in each group. Results ① The BNP level in group D was lower than that in group C (P <0.05). ② The LVEF in group D was higher than that in group C (P <0.05). ③ The pathological changes in group C and D were alleviated (P <0.01). Conclusion Perindopril combined with irbesartan in DCM rats is better than single perindopril in improving cardiac function. Both of the two regimens can reduce the pathological damage of myocardium.